University of Zurich

Swiss and neighbouring institutes pioneer AAV-based delivery of prime editors for in-vivo correction of inherited metabolic liver defects.

Country: Switzerland

Research institute

Coverage

	CN	EU	US
genome-engineering	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Affiliation	Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland	doi.org
Research focus	Development of CRISPR-based genome editing tools including base and prime editors for in vivo treatment of inherited metabolic diseases such as phenylketonuria, citrullinemia type I, and hypercholesterolemia	doi.org · itinerare.uzh.ch · labmanager.com · news.uzh.ch
Facility	Schwank Lab, Institute of Pharmacology and Toxicology, University of Zurich	doi.org
Grant	SNSF grant no. 310030_185293, SERI funded ERC-CoG 'GeneRepair', UZH Research Priority Programs (ITINERARE, Human Reproduction Reloaded), Novartis Foundation for Medical-Biological Research no. FN20-0000000203, SNSF Spark fellowship no. 196287, University Zürich Candoc grant no. FK-22-033	doi.org
Publications	Peer-reviewed articles in journals such as Science Translational Medicine, Nature Biomedical Engineering, and bioRxiv regarding in vivo prime editing for metabolic liver defects	doi.org
Principal staff	Gerald Schwank (Professor and Group Leader), Tatjana Haenggi (Lab Manager)	doi.org · schwanklab.org · med.uzh.ch

Independent sources: doi.org · itinerare.uzh.ch · labmanager.com · med.uzh.ch · news.uzh.ch · schwanklab.org

Technologies

Name	Cluster	Risk
Prime editing	genome-engineering	High	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.